6 results on '"OVERALL survival"'
Search Results
2. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.
3. Clinical Updates: PROSTATE CANCER. Darolutamide delays time to progression from mHSPC to mCRPC vs placebo.
4. Clinical Updates: PROSTATE CANCER. Survival may be improving in de novo mHSPC, new data suggest.
5. Clinical Updates: BLADDER CANCER. Adding durvalumab to chemotherapy extends survival in MIBC.
6. Blue light cystoscopy decreases risk of recurrence, progression in NMIBC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.